The firm reported that it expects product and service revenue of approximately $23.5 million for the fourth quarter of last year and $83.5 million for full-year 2018.
The companies announced a strategic venture to provide comprehensive biomarker profiling to empower clinical trials in the immuno-oncology space.
The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.
The technology could eventually have applications in pathology as well as field-based diagnostic testing for infectious diseases.
The assay analyzes a digital image of tumor tissue sample to identify ER-positive breast cancer patients who are candidates for adjuvant chemotherapy.
Sunquest now offers GeneInsight as part of its laboratory information management system solution and is working with Partners to develop new capabilities for the clinical genomics tool.
The technical-only testing service leverages Ventana's digital pathology technology.
NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.
Flagship Biosciences will use Affymetrix Quantigene ViewRNA assays as part of a new tissue-based RNA in situ hybridization analysis service.
NEW YORK (GenomeWeb News) – Definiens today said that it has raised €10 million ($12.9 million) in a private round of financing.
According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.
Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.
In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.